The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York, New York 10021, USA.
Semin Reprod Med. 2010 Nov;28(6):519-31. doi: 10.1055/s-0030-1265680.
The only reliable way to eliminate the risk of ovarian hyperstimulation syndrome (OHSS) is complete avoidance of gonadotropin ovarian stimulation. It could be argued that in vitro maturation (IVM) of oocytes represents the most effective strategy to prevent OHSS. IVM has been an established treatment option in many centers worldwide for over a decade. The use of IVM and natural cycle in vitro fertilization (IVF) combined with IVM can result in clinical pregnancy rates that compare to those obtained with conventional IVF. The obstetric and perinatal outcomes of IVM pregnancies are similar to those conceived from stimulated IVF or spontaneous conceptions. To date, more than a thousand healthy infants have been born without an increase in fetal abnormalities. Although IVM may not replace standard IVF, it plays an increasingly important role in assisted reproductive technology, especially in the settings of high responders and those patients at risk of OHSS.
消除卵巢过度刺激综合征 (OHSS) 风险的唯一可靠方法是完全避免促性腺激素卵巢刺激。可以说,卵母细胞体外成熟 (IVM) 代表了预防 OHSS 的最有效策略。十多年来,IVM 在世界许多中心已成为一种既定的治疗选择。IVM 和自然周期体外受精 (IVF) 与 IVM 的联合应用可导致临床妊娠率与传统 IVF 获得的妊娠率相当。IVM 妊娠的产科和围产期结局与通过刺激 IVF 或自然受孕获得的妊娠相似。迄今为止,已有一千多名健康婴儿出生,没有胎儿畸形增加的情况。虽然 IVM 可能无法替代标准的 IVF,但它在辅助生殖技术中发挥着越来越重要的作用,尤其是在高反应者和有 OHSS 风险的患者中。